Exclusive Speaker Interview from Janssen for SMi’s ADC Conference 2018

SMi are delighted to welcome Aman Singh, PK-PD Scientist, Janssen, onto the speaker panel for day 1 at ADC 2018!

Aman received his Master’s in Pharmacometrics from Department of Pharmaceutical Sciences, UB from Dr. Wojciech Krzyzanski’s lab in 2012 working on translational PKPD models for monoclonal antibodies. He joined Dr. Dhaval Shah’s lab in 2013 for his PhD working on different aspects of Antibody-Drug Conjugates (ADCs). He is currently working the Biologics Development Sciences Department of Janssen R&D as PK-PD Scientist.

Besides that, he also has industrial experience in different modeling and simulation positions in Pfizer, Cognigen Corporation and Genentech.

We are excited to have interviewed Aman about his talk and career experience.

Below is a snapshot of his interview:

Q. What technology or platform updates have really caught your eye in the past couple of years?

A. CD3 Redirecting antibodies, Radio-immunoconjugates, site-specific ADCs

Q. What are the key areas for development in the field of ADCs?

A. Overcoming binding site barrier for successful tumor penetration, Bystander effect of ADCs, preclinical to clinical translation

Q. What are the future challenges for the advancement of ADCs and what do you think are the biggest hindrances to achieving the utmost therapeutic potential of ADCs?

Check out the full interview, available in the download centre:

Hear more from Aman at the Antibodies & Antibody Drug Conjugates conference this April 2018, as he presents 'Application of a PK-PD Modeling & Simulation in Antibody-Drug Conjugate Development.' - Day 1 | @09:50

Topics will explore:

- Preclinical to clinical translation: The routes through which ADCs can be evolved into applicable settings
- Bystander effect of ADCs - How the presence of antigen expressing cells can induce additional efficacy of the ADC and can cause antigen negative cells to express cytotoxicity
- The rapid binding and immobilisation of ADCs their entry site, prohibits the diffusion of the drug further away from the blood vessel. This is termed as the binding site barrier effect
- Cell-level pharmacokinetics of ADCs and the effect that this has on drug efficacy and efficiency

Further information is available at: www.adcsummit.com/opr

SMi presents the 6th Annual Conference:
ADC Summit
Date: 9th – 10th April 2018
Location: Copthorne Tara Hotel, London UK
Website: www.adcsummit.com/opr

---end---

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Westminster Bridge Road
1

This release was published on openPR.